ID

19693

Descrizione

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00356681

collegamento

https://clinicaltrials.gov/show/NCT00356681

Keywords

versioni (1)
  1. 22/01/17 22/01/17 -
Caricato su

22 gennaio 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Breast Neoplasms NCT00356681

Inglese

Eligibility Breast Neoplasms NCT00356681

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease.
Descrizione

Breast adenocarcinoma | Recurrent disease Local | Neoplasm Metastasis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0858252
UMLS CUI [2,1]
C0277556
UMLS CUI [2,2]
C0205276
UMLS CUI [3]
C0027627
measurable disease by recist guidelines.
Descrizione

Measurable Disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1513041
tumor (primary or metastatic) must be her2 negative.
Descrizione

Human epidermal growth factor 2 negative carcinoma of breast Primary | Human epidermal growth factor 2 negative carcinoma of breast metastatic

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2316304
UMLS CUI [1,2]
C0205225
UMLS CUI [2,1]
C2316304
UMLS CUI [2,2]
C1522484
adequate organ and hematologic function. exclusion:
Descrizione

organ function | Hematologic function | Exclusion

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0678852
UMLS CUI [2]
C0221130
UMLS CUI [3]
C2828389
taxane treatment within 12 months prior to registration.
Descrizione

taxane

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0215136
prior chemotherapy for locally recurrent or metastatic breast cancer (prior endocrine therapy is permitted).
Descrizione

Chemotherapy Breast cancer recurrent Local | Chemotherapy Secondary malignant neoplasm of female breast | Hormone Therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0278493
UMLS CUI [1,3]
C0205276
UMLS CUI [2,1]
C0392920
UMLS CUI [2,2]
C0346993
UMLS CUI [3]
C0279025
prior radiation therapy, radiofrequency ablation, percutaneous cryotherapy or hepatic chemoembolization on all sites of measurable disease.
Descrizione

Therapeutic radiology procedure | Radiofrequency ablation | Cryosurgery Percutaneous | Chemoembolization of hepatic artery Measurable Disease Site All

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1522449
UMLS CUI [2]
C0850292
UMLS CUI [3,1]
C0010408
UMLS CUI [3,2]
C0522523
UMLS CUI [4,1]
C2711393
UMLS CUI [4,2]
C1513041
UMLS CUI [4,3]
C1515974
UMLS CUI [4,4]
C0444868
current or prior history of central nervous system metastases.
Descrizione

CNS metastases

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0686377
peripheral neuropathy ≥ grade 2 (ctcae v3.0) at registration.
Descrizione

Peripheral Neuropathy CTCAE Grades

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C1516728
history of arterial or venous thrombosis within 1 year prior to registration.
Descrizione

Arterial thrombosis | Venous Thrombosis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0151942
UMLS CUI [2]
C0042487
history of bleeding diathesis or bleeding within 14 days of registration.
Descrizione

Bleeding tendency | Hemorrhage

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1458140
UMLS CUI [2]
C0019080
uncontrolled hypertension (systolic >145 mmhg; diastolic >85 mmhg).
Descrizione

Uncontrolled hypertension | Systolic Pressure | Diastolic blood pressure

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1868885
UMLS CUI [2]
C0871470
UMLS CUI [3]
C0428883
clinically significant cardiac disease within 12 months of registration.
Descrizione

Heart Disease Clinical Significance

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0018799
UMLS CUI [1,2]
C2826293
known hiv positive, hepatitis c positive or hepatitis b surface antigen positive.
Descrizione

HIV Seropositivity | Hepatitis C positive | Hepatitis B surface antigen positive

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019699
UMLS CUI [2]
C1112419
UMLS CUI [3]
C0149709
prior treatment with vegfr targeted therapies.
Descrizione

Targeted Therapy VEGFR

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2985566
UMLS CUI [1,2]
C0148199
Ritorna all'inizio della pagina

Similar models

Eligibility Breast Neoplasms NCT00356681

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Breast adenocarcinoma | Recurrent disease Local | Neoplasm Metastasis
Item
histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease.
boolean
C0858252 (UMLS CUI [1])
C0277556 (UMLS CUI [2,1])
C0205276 (UMLS CUI [2,2])
C0027627 (UMLS CUI [3])
Measurable Disease
Item
measurable disease by recist guidelines.
boolean
C1513041 (UMLS CUI [1])
Human epidermal growth factor 2 negative carcinoma of breast Primary | Human epidermal growth factor 2 negative carcinoma of breast metastatic
Item
tumor (primary or metastatic) must be her2 negative.
boolean
C2316304 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C2316304 (UMLS CUI [2,1])
C1522484 (UMLS CUI [2,2])
organ function | Hematologic function | Exclusion
Item
adequate organ and hematologic function. exclusion:
boolean
C0678852 (UMLS CUI [1])
C0221130 (UMLS CUI [2])
C2828389 (UMLS CUI [3])
taxane
Item
taxane treatment within 12 months prior to registration.
boolean
C0215136 (UMLS CUI [1])
Chemotherapy Breast cancer recurrent Local | Chemotherapy Secondary malignant neoplasm of female breast | Hormone Therapy
Item
prior chemotherapy for locally recurrent or metastatic breast cancer (prior endocrine therapy is permitted).
boolean
C0392920 (UMLS CUI [1,1])
C0278493 (UMLS CUI [1,2])
C0205276 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2,1])
C0346993 (UMLS CUI [2,2])
C0279025 (UMLS CUI [3])
Therapeutic radiology procedure | Radiofrequency ablation | Cryosurgery Percutaneous | Chemoembolization of hepatic artery Measurable Disease Site All
Item
prior radiation therapy, radiofrequency ablation, percutaneous cryotherapy or hepatic chemoembolization on all sites of measurable disease.
boolean
C1522449 (UMLS CUI [1])
C0850292 (UMLS CUI [2])
C0010408 (UMLS CUI [3,1])
C0522523 (UMLS CUI [3,2])
C2711393 (UMLS CUI [4,1])
C1513041 (UMLS CUI [4,2])
C1515974 (UMLS CUI [4,3])
C0444868 (UMLS CUI [4,4])
CNS metastases
Item
current or prior history of central nervous system metastases.
boolean
C0686377 (UMLS CUI [1])
Peripheral Neuropathy CTCAE Grades
Item
peripheral neuropathy ≥ grade 2 (ctcae v3.0) at registration.
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Arterial thrombosis | Venous Thrombosis
Item
history of arterial or venous thrombosis within 1 year prior to registration.
boolean
C0151942 (UMLS CUI [1])
C0042487 (UMLS CUI [2])
Bleeding tendency | Hemorrhage
Item
history of bleeding diathesis or bleeding within 14 days of registration.
boolean
C1458140 (UMLS CUI [1])
C0019080 (UMLS CUI [2])
Uncontrolled hypertension | Systolic Pressure | Diastolic blood pressure
Item
uncontrolled hypertension (systolic >145 mmhg; diastolic >85 mmhg).
boolean
C1868885 (UMLS CUI [1])
C0871470 (UMLS CUI [2])
C0428883 (UMLS CUI [3])
Heart Disease Clinical Significance
Item
clinically significant cardiac disease within 12 months of registration.
boolean
C0018799 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
HIV Seropositivity | Hepatitis C positive | Hepatitis B surface antigen positive
Item
known hiv positive, hepatitis c positive or hepatitis b surface antigen positive.
boolean
C0019699 (UMLS CUI [1])
C1112419 (UMLS CUI [2])
C0149709 (UMLS CUI [3])
Targeted Therapy VEGFR
Item
prior treatment with vegfr targeted therapies.
boolean
C2985566 (UMLS CUI [1,1])
C0148199 (UMLS CUI [1,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial